DAPA-HF Trial: Dapagliflozin in Heart Failure Patients without Diabetes

The DAPA-HF trial investigated the use of dapagliflozin, an SGLT2 inhibitor, in patients with heart failure and reduced ejection fraction, regardless of diabetes status. Funded by AstraZeneca, the study enrolled 4,744 patients from 20 countries, showing promising results in reducing cardiovascular d

3 views • 22 slides